Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 32c
Get Alerts VNDA Hot Sheet
Revenue Growth %: +59,101.9%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.14, $0.32 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $47.35 million versus the consensus estimate of $47.28 million.
"We are excited with the year to date HETLIOZ sales performance, which demonstrates continued strength, and our HETLIOZ life cycle management program, which positions the product well for additional future growth," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. \"We are focused on our upcoming clinical milestones from the tradipitant gastroparesis study and the HETLIOZ Smith-Magenis Syndrome study."
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) down despite beating Q1 estimates on top and bottom lines
- Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
- Procter & Gamble (PG) Tops Q3 EPS by 11c, Revenues Miss
Create E-mail Alert Related Categories
Earnings, Guidance, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!